In this series of interviews, Theratrame’s CSO Dr Pierre Close, had the opportunity to discuss and share his experience on the past, present and future challenges faced by biotechnology companies. (25) Activity | Nadia Guarini | LinkedIn ...

Theratrame is pioneering a novel therapeutic strategy targeting tRNA epitranscriptomics through ELP3 inhibition. This differentiated approach combines direct anti-tumor activity with immune modulation. click here for more information. ...

The company has presented its platform at leading conferences such as Discovery on Target (Boston) and collaborates with industry partners like Axxam. These engagements reinforce Theratrame’s growing recognition in the global biotech ecosystem. click here for more information. ...

Theratrame’s CEO, Dr. Francesca Rapino, was recognized as Biotech CEO of the Year  for her contributions to oncology innovation. This distinction highlights the company’s scientific leadership and strategic vision. ” https://www.prnewswire.com/news-releases/dr-francesca-rapino-of-theratrame-sa-named-in-business-worldwide-magazines-2025-ceo-awards-302545587...

We are delighted to unveil our new logo , which marks a significant milestone in our company's evolution. This renewed identity reflects our commitment to improving patient health , promoting scientific excellence , and our drive to advance biotechnology , while emphasizing the important and central role of tRNAs . ...